Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT by Edan, Gilles et al.
Long-term impact of interferon beta-1b in patients with
CIS: 8-year follow-up of BENEFIT
Gilles Edan, Ludwig Kappos, Xavier Montalba´n, Chris Polman, Mark
Freedman, Hans-Peter Hartung, D Miller, F Barkhof, Julia Herrmann, Vivian
Lanius, et al.
To cite this version:
Gilles Edan, Ludwig Kappos, Xavier Montalba´n, Chris Polman, Mark Freedman, et al.. Long-
term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT. Journal
of Neurology, Neurosurgery and Psychiatry, BMJ Publishing Group, 2013, 85, pp.1183-1189.
<10.1136/jnnp-2013-306222>. <inserm-01103090>
HAL Id: inserm-01103090
http://www.hal.inserm.fr/inserm-01103090
Submitted on 14 Jan 2015
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.

RESEARCH PAPER
Long-term impact of interferon beta-1b in patients
with CIS: 8-year follow-up of BENEFIT
G Edan,1 L Kappos,2 X Montalbán,3 C H Polman,4 M S Freedman,5 H-P Hartung,6
D Miller,7 F Barkhof,8 J Herrmann,9 V Lanius,10 B Stemper,10 C Pohl,10,11
R Sandbrink,6,10 D Pleimes,12 for the BENEFIT Study Group
▸ Additional material is
published online only. To view
please visit the journal online
(http://dx.doi.org/10.1136/
jnnp-2013-306222).
For numbered afﬁliations see
end of article.
Correspondence to
Professor Ludwig Kappos,
Neurology and Department of
Research, University Hospital
Basel, Petersgraben 4, Basel
4031, Switzerland; Ludwig.
Kappos@usb.ch
GE, LK, RS and DP contributed
equally to this study.
The Beneﬁt study group
members are listed in
appendix 1.
Received 28 June 2013
Revised 4 October 2013
Accepted 7 October 2013
Published Online First
11 November 2013
▸ http://dx.doi.org/10.1136/
jnnp-2013-306720
To cite: Edan G, Kappos L,
Montalbán X, et al. J Neurol
Neurosurg Psychiatry
2014;85:1183–1189.
ABSTRACT
Objective To examine the long-term impact of early
treatment initiation of interferon beta-1b (IFNB1b,
Betaferon/Betaseron) in patients with a ﬁrst event
suggestive of multiple sclerosis (MS).
Methods In the original placebo-controlled phase of
BENEFIT, patients were randomised to IFNB1b 250 μg or
placebo subcutaneously every other day. After 2 years or
diagnosis of clinically deﬁnite MS (CDMS), all patients
were offered open-label IFNB1b treatment for a
maximum duration of 5 years. Thereafter, patients were
enrolled in an observational extension study for up to
8.7 years.
Results Of the initial 468 patients, 284 (60.7%;
IFNB1b: 178 (61.0% of the original arm), placebo: 106
(60.2% of original arm)) were enrolled in the extension
study. 94.2% of patients were receiving IFNB1b. Patients
originally randomised to IFNB1b had a reduced risk of
developing CDMS by 32.2% over the 8-year observation
period (HR 0.678; 95% CI 0.525 to 0.875; p=0.0030),
a longer median time to CDMS by 1345 days (95% CI
389 to 2301), and a lower annualised relapse rate
(0.196 (95% CI 0.176 to 0.218) versus 0.255 (95% CI
0.226 to 0.287), p=0.0012), with differences mainly
emerging in the ﬁrst year of the study. Cognitive
outcomes remained higher in the early treated patients.
EDSS remained low over time with a median of 1.5 in
both arms.
Conclusions These 8-year results provide further
evidence supporting early initiation of treatment with
IFNB1b in patients with a ﬁrst event suggestive of MS.
INTRODUCTION
Multiple sclerosis (MS) is a chronic inﬂammatory
disease of the central nervous system that can lead
to the accumulation of signiﬁcant disability.1 As the
disease typically lasts for several decades, long-term
follow-up studies are important to better under-
stand the impact of disease-modifying therapies
(DMTs). However, conducting these trials can be
challenging due to many methodological barriers,
including the difﬁculties associated with patient
ascertainment.2
Clinical trials have shown that the early initiation of
treatment with interferon beta-1b (IFNB1b;
Betaferon/Betaseron; Bayer HealthCare
Pharmaceuticals) can improve outcomes for patients
with MS. The BENEFIT (BEtaferon/BEtaseron in
Newly Emerging MS For Initial Treatment) study
examined the impact of IFNB1b in patients with a
clinically isolated syndrome (CIS). In this trial, early
IFNB1b treatment reduced the number of patients
progressing to clinically deﬁnite MS (CDMS) com-
pared with placebo after 3 years (37% vs 51%, hazard
ratios (HR) 0.59) and 5 years (46% vs 57%, HR
0.63).3 4 Annualised relapse rate (ARR) and Paced
Auditory Serial Addition Task (PASAT) scores were
also in favour of the early treatment arm.3 4
We report results of an 8-year, non-interventional
extension of BENEFIT focusing on the description
of the course of disease in the overall study popula-
tion and on the comparison of outcomes in the
early versus delayed treatment arms.
METHODS
Patients and procedures
The BENEFIT study comprised a prospective,
2-year, international, multicentre, randomised,
double-blind, placebo-controlled, parallel-group,
phase 3 study with a preplanned follow-up phase
of up to 5 years, followed by an observational
extension study (NCT00544037) for a maximum
follow-up of 8.7 years. The protocol was approved
by the institutional review boards of the participat-
ing institutions, and informed consent was col-
lected at enrolment into each phase.3–5 Eligible
patients had experienced a ﬁrst neurological event
suggestive of MS (CIS) and had at least two clinic-
ally silent lesions on T2-weighted brain MRI.
Within 60 days, patients were randomly assigned in
a 5:3 ratio to IFNB1b 250 mg or placebo subcuta-
neously every other day. Patients completed the
placebo-controlled phase when CDMS was diag-
nosed using Poser criteria6 or after 2 years in the
study (whichever came ﬁrst) and were then eligible
to enter the open-label, single-arm, follow-up study
for up to 5 years during which all patients were
offered IFNB1b, but could also opt to take other
or no medication. Blinding of the initial randomisa-
tion was maintained throughout the 5-year period.
Prospectively planned integrated analyses were per-
formed at 3 5 years after the ﬁrst event suggestive
of MS.3 4
All 468 patients randomised and treated at least
once with study medication in the placebo-
controlled phase were eligible to enter the observa-
tional extension study in which treatment decisions
were made exclusively at the discretion of physi-
cians and patients. Physicians recorded any medica-
tions for MS that were administered. Prior to the
end of the BENEFIT Extension study, the steering
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committee identiﬁed a list of therapies that were deﬁned as
DMTs. Of this list, a subset was considered as escalation therapy
(ﬁgure 1).
Evaluations were performed at baseline and every 6 months
until December 2010. MRI outcomes, including time to
McDonald MS, could not be sufﬁciently assessed in the observa-
tional extension study. No serum samples were taken in the
extension phase. Neutralising antibodies (NAbs) were thor-
oughly assessed in the 5-year interventional follow-up phase.7
In addition to the original key outcome measures time to
CDMS, ARR, and sustained Expanded Disability Status Scale
(EDSS) score,3 4 time to ﬁrst escalation therapy was included as
an outcome in the extension study. Sustained EDSS progression
was deﬁned as an increase by ≥1 point at two consecutive
scheduled visits (at least 140 days apart) and maintained
throughout all subsequent scheduled or unscheduled visits in
the study as compared with the lowest EDSS score during
screening or baseline. Scores obtained during relapses were
included. Additional outcome measures included the MS
Functional Composite (MSFC),8 conversion to Secondary
Progressive MS, and patient-reported quality of life (QoL) as
measured by the Functional Assessment of MS (FAMS), the
FAMS-Trial Outcome Index (FAMS-TOI)9 and the EuroQoL 5-
Dimensional questionnaire (EQ-5D).10
Statistical analyses
Statistical analyses were conducted on the dataset of the entire
BENEFITstudy period. All variables were analysed by descriptive
statistical methods. Efﬁcacy was analysed in three domains:
relapse-based, disability-based and patient-reported outcome-
based variables (see online supplemental appendix 2). Most vari-
ables in the ﬁrst domain were time-to-event variables described
by Kaplan–Meier estimates, and treatment groups were com-
pared by a log-rank test and proportional hazards regression
(covariates: randomised treatment, steroid use during the ﬁrst
clinical event, type of disease onset and categorised number of
T2 lesions on BENEFIT screening MRI). The variables in the last
two domains were mainly analysed using non-parametric and/or
parametric longitudinal modelling. Predeﬁned statistical model-
ling procedures were used to estimate treatment effects and
explore the relationship of target variables to treatment and prog-
nostic covariates. Use of DMTs was analysed by descriptive statis-
tical methods.
Role of the funding source
The study was designed by members of the steering committee
and the study sponsor. The authors had access to all the data,
participated in analysis and interpretation, and were members of
the publication committee. The decision to submit the article
for publication was made jointly by the members of the steering
committee.
RESULTS
Patient disposition and demographics
Of the 468 patients originally randomised in the BENEFIT
study (IFNB1b: 292; placebo: 176),6 284 patients (60.7%) were
enrolled in the extension phase (178 patients (61.0%) originally
randomised to IFNB1b (early treatment group) and 106 patients
(60.2%) originally randomised to placebo (delayed treatment
group), see online supplemental ﬁgure S1). These patients were
recruited from 72 of the 97 initial centres in 17 of the 20 initial
countries. Excluding patients from non-participating sites
(which is likely to be a random rather than a selection bias), the
enrolment rate was 67.8%. Fifty-ﬁve per cent of patients
(including all sites) completed the extension study (61.6%
excluding non-participating sites). Baseline characteristics were
generally similar across the two groups on entry to the rando-
mised and extension phases (table 1). Patients who entered the
extension study after 5 years had experienced a higher rate of
conversion to CDMS (50.7% vs 40.2%) and McDonald MS
(85.2% vs 74.5%) than patients who did not enter the exten-
sion phase.
DMT and escalation therapy usage
Of the original 468 patients, 441 (94.2%) received IFNB1b
since the start of BENEFIT. The median relative time (MRT) on
Figure 1 Proportion of patients
requiring escalation therapy pooled
across total population. The majority of
patients did not require escalation
therapy during the study. The
treatments used by the 6.6% who
required escalation therapy are shown
in the inset box. Escalation therapies
included alemtuzumab, cyclosporine,
cladribine, cyclophosphamide,
daclizumab, ﬁngolimod, ﬁngolimod
hydrochloride, methotrexate,
methotrexate sodium, mitoxantrone,
mitoxantrone hydrochloride,
mycophenolate mofetil, mycophenolate
sodium, natalizumab, rituximab,
sirolimus, tacrolimus and temsirolimus.
aWhen multiple therapies are listed,
the order indicates the sequence of
therapies. Inset box lists only the
escalation therapies administered
during the study. Escalation therapy
was generally similar between groups,
with the exception of natalizumab
(early treatment, 10 patients (3.4%);
delayed treatment, 9 patients (5.1%)).
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study drug (the time on study drug relative to the time under
observation) was 75.2% among patients taking IFNB1b at least
once. For 363 patients (77.6%), IFNB1b was the only DMT
recorded at any time. More than half the patients (55.6%) in
the overall study population were still on IFNB1b within the
90-day period before their last study day. Other DMTs adminis-
tered at some point over the 8-year observation period included
interferon beta-1a (Avonex, Biogen Idec; 28 patients (6.0%),
MRT 19.0%) and glatiramer acetate (Copaxone, Teva
Neuroscience; 27 patients (5.8%), MRT 23.8%). In the delayed
treatment arm, the length of placebo exposure was a minimum
of 1 month and a median of 23.0 months (mean 17.5 months).
Only 24 patients (5.1%) received no DMT. Eighty-three percent
(142/171) of patients taking IFNB1b at least once in the exten-
sion study were still on this treatment within the 90-day period
before their last study day.
Overall, the percentage of patients who underwent escalation
therapy remained low. Only 31 patients (6.6%) received other
DMTs that were considered escalation therapies over the course
of the 8-year study, in most cases natalizumab (ﬁgure 1). Sixteen
of these 31 patients subsequently stopped their ﬁrst escalation
therapy within the study period; four subsequently used ≥1
therapy. At the end of the study period, the probability of
patients requiring ﬁrst escalation therapy remained low and was
similar in both the early and delayed treatment groups (Kaplan–
Meier estimates 9.3% vs 10.7% as of year 8). Among the
patients who received escalation therapy, the ARR was 0.617
(95% CI 0.518 to 0.729) versus 0.185 (95% CI 0.169 to 0.202)
in those who did not receive therapeutic escalation. The last
available EDSS value prior to the patient’s ﬁrst therapeutic escal-
ation was higher (median 2.5) than in the whole study
population.
Study outcomes
At the end of the 8-year observational period, the risk for devel-
opment of CDMS in the early treatment group was lower than
that of the delayed treatment group by 32.2% (HR 0.678, 95%
CI 0.525 to 0.875; p=0.0030, log-rank test; ﬁgure 2). Based on
Kaplan–Meier estimates, early treatment with IFNB1b reduced
the probability of the development of CDMS over the 8 years
(55.5% early treatment vs 65.8% delayed) with differences
emerging between the treatment arms in the ﬁrst year. At the
50th percentile, IFNB1b prolonged the time to CDMS by
1345 days (3.7 years, 95% CI 389 to 2301; 2335 days
(6.5 years) in the early versus 990 days (2.8 years) in the delayed
treatment group.
The overall ARR in the 8-year observational period was lower
in the early treatment group than in the delayed treatment
group (0.196 (95% CI 0.176 to 0.218) versus 0.255 (95% CI
0.226 to 0.287); ﬁgure 3). According to the generalised linear
Poisson regression model, early treatment with IFNB1b reduced
the ARR by 22.9% over the 8-year period compared with
delayed treatment (risk ratio=0.771 (95% CI 0.659 to 0.903);
p=0.0012, Wald-type χ2 test). Additionally, risk of recurrent
relapses was reduced by 23.4% with early treatment (HR 0.766,
95% CI 0.589 to 0.998; p=0.048). In a post hoc analysis of
ARR data, differences between treatment arms emerged in the
ﬁrst year of the study, with signiﬁcant differences seen in com-
bined year 1 and 2 relapse rates (early treatment: 0.233 (95%
CI 0.195 to 0.277) versus delayed treatment: 0.325 (95% CI
0.268 to 0.392); p=0.0073; Wald-type χ2 test from generalised
linear Poisson regression model; RR=0.705, 95% CI 0.546 to
0.910). This difference was maintained when aggregated relapse
rates from years 3 to 8 were analysed (early treatment: 0.180
(95% CI 0.157 to 0.205) versus delayed treatment: 0.223 (95%
CI 0.190 to 0.260); p=0.037; RR=0.807, 95% CI 0.660 to
0.987).
There was little change from mean EDSS score at baseline/
screening over the 8-year observation period, and scores were
similar between the treatment groups (table 2). In both groups,
the median EDSS remained 1.5 from baseline to 8 years. EDSS
was stable or improved from baseline to last visit during the
Table 1 Baseline characteristics of patients who did and did not enter the BENEFIT Extension study (A) at the start of the placebo-controlled
phase of BENEFIT and (B) at the start of the extension study
(A)
Baseline characteristics
Did not enter BENEFIT extension Entered BENEFIT extension
Early treatment Delayed treatment Overall Early treatment Delayed treatment Overall
n 114 70 184 178 106 284
Age (years), median (Q1–3) 29.0 (24.0–38.0) 30.5 (27.0–37.0) 30.0 (25.0–37.0) 30.0 (24.0–37.0) 30.0 (24.0–35.0) 30.0 (24.0–36.5)
Female, % 70.2 70.0 70.1 71.3 70.8 71.1
Multifocal onset, % 42.1 48.6 44.6 51.1 46.2 49.3
Steroid treatment at first event, % 75.4 70.0 73.4 69.1 69.8 69.4
Number of T2 lesions, median (Q1–3) 18.0 (8.0–36.0) 18.5 (6.0–34.0) 18.0 (7.0–35.5) 18.0 (7.0–39.0) 16.0 (8.0–37.0) 17.0 (7.0–38.5)
Number of Gd-enhancing lesions, median (Q1–3) 0.0 (0.0–1.0) 0.0 (0.0–1.0) 0.0 (0.0–1.0) 0.0 (0.0–1.0) 0.0 (0.0–1.0) 0.0 (0.0–1.0)
EDSS at baseline median (mean), Q1–3 1.5 (1.64), 1.0–2.0 1.5 (1.53), 1.0–2.0 1.5 (1.60), 1.0–2.0 1.5 (1.55), 1.0–2.0 1.5 (1.46), 1.0–2.0 1.5 (1.52), 1.0–2.0
At start of extension study
Did not enter BENEFIT extension Entered BENEFIT extension
(B) Early treatment Delayed treatment Overall Early treatment Delayed treatment Overall
n 114 70 184 178 106 284
CDMS, n (%) 40 (35.1) 34 (48.6) 74 (40.2) 84 (47.2) 60 (56.6) 144 (50.7)
McDonald MS,n (%) 81 (71.1) 56 (80.0) 137 (74.5) 144 (80.9) 98 (92.5) 242 (85.2)
EDSS, median (mean), Q1–3 1.5 (1.55), 1.0–2.0 1.5 (1.67), 1.0–2.0 1.5 (1.60), 1.0–2.0 1.5 (1.51), 1.0–2.0 1.5 (1.51), 1.0–2.0 1.5 (1.51), 1.0–2.0
CDMS, clinically definite multiple sclerosis; EDSS, Expanded Disability Status Scale; Gd, gadolinium; MS, multiple sclerosis; Q1–3, 1st to 3rd quartile.
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extension in 68.3% of patients and was worse in 31.7%.
Non-parametric longitudinal modelling found no effects of time
(p=0.28) or treatment (p=0.9008) on EDSS scores.
No signiﬁcant differences between treatment groups, and a
slight overall decrease (p=0.027) in MSFC mean z-scores
including the subscores for the 9-hole peg test and 25-foot
walk, were observed over the 8-year study period, although a
signiﬁcant increase (p=0.0453) in PASAT z-score in favour of
early treatment was maintained over the whole study period
(see online supplemental ﬁgure S2). Throughout the 8-year
observational period, QoL as measured by FAMS-TOI (see
online supplemental ﬁgure S3) and EQ-5D rating scales
remained high, without signiﬁcant differences between the two
treatment groups (data not shown).
Neutralising antibodies
Only 39 (n=25 (14.1%) IFNB1b arm; n=14 (13.2%) placebo
arm) of the patients enrolled in BENEFIT Extension were NAb+
at their last assessment in the interventional follow-up phase of
BENEFIT. When data were stratiﬁed into four groups (NAb:-
<20 NU/mL, NAb+: ≥20 to <100 NU/mL, ≥100 to
<400 NU/mL, ≥400 NU/mL), no differences in EDSS or con-
version to CDMS were identiﬁed. Median EDSS was 1.5, 1.5,
2.0 and 1.5, respectively, in these groups at their last visit in the
Figure 3 Annualised relapse rate (ARR) by year in the total number of patients observed overall and during each study year. ARR was signiﬁcantly
lower in the early treatment group than in the delayed treatment group over the entire study period as well as in years 1 and 8. ARR was lower
among patients in the early treatment than the delayed treatment group for years 1 and 2 (0.233 (95% CI 0.195 to 0.277) vs 0.325 (95% CI 0.268
to 0.392), p=0.0073a; RR=0.705, 95% CI 0.546 to 0.910) and from years 6 to 8 (0.146 (95% CI 0.115 to 0.184)) vs 0.212 (95% CI 0.164 to 0.270);
p=0.032a; RR=0.694, 95% CI 0.497 to 0.969). aWald-type χ2 test. Generalised linear Poisson regression model.
Figure 2 Kaplan–Meier estimates for
the probability of CDMS over 8 years.
Probability of conversion to CDMS was
signiﬁcantly higher in the delayed
treatment group. At the 50th
percentile, conversion to CDMS was
delayed by approximately 3.7 years in
the early treatment group. aBy
proportional hazards regression,
adjusted for steroid use during the ﬁrst
clinical event, type of disease onset,
and categorised number of T2 lesions
on BENEFIT screening MRI. CDMS,
clinically deﬁnite multiple sclerosis.
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extension study. Thus, descriptive analyses neither showed an
increased rate of conversion to CDMS nor EDSS progression
during the non-interventional extension period in patients who
were NAb+ at the end of the interventional study.
Safety and tolerability results
In the extension study, the frequency of adverse events (AEs)
was within the well-established safety and tolerability proﬁle for
IFNB1b; there were no new unexpected safety signals. The total
number of patients experiencing ≥1 serious AEs (SAE) in the
extension study was similar in each group: 12 patients (6.7%) in
the early treatment group and eight patients (7.5%) in the
delayed treatment group. Almost all SAEs were reported to be
unrelated to IFNB1b, as assessed by the investigators.
DISCUSSION
In this observational extension of the BENEFIT trial, patient
ascertainment remained modestly high after 8 years with little
difference in baseline characteristics when participating patients
were compared with those not entering the extension. Overall,
patients in both the early and the delayed treatment groups who
entered the BENEFIT Extension tended to have had more
active disease during the double-blind study, as depicted by
higher rates of CDMS and McDonald MS. This would be
expected to reduce the differences between treatment groups.
However, signiﬁcant differences between early and delayed
treatment were still observed.
Patients who received early treatment had a lower risk of con-
version to CDMS, lower ARR and longer time to recurrent
relapses than those who received delayed treatment, differences
that persisted throughout the study. After 8 years, 51.9%
(45.5% by Kaplan–Meier estimates) of the patients who
received early treatment in BENEFIT had not converted to
CDMS, which contrasts with the subgroup of the CIS cohort
reported by Fisniku et al11 with ≥1 clinically silent MRI lesion
at screening in which only 17% had not converted to CDMS
after 9.7 years. Although the differences in outcomes appear to
be mainly driven by treatment effects that emerged in the ﬁrst
year of the BENEFIT study and would be expected to dissipate
as patients in the delayed treatment arm accumulated more time
on IFNB1b, earlier treatment seemed to have continued beneﬁts
over the long term. For example, although differences in ARR
across treatment groups were mainly driven by treatment effects
in the ﬁrst year of the study, a signiﬁcant difference between
treatment arms was still found across years 3–8, which might
indicate a prolonged beneﬁt due to an immunomodulatory shift
that cannot be recovered in the delayed treatment group.
Early treatment also appeared to provide some cognitive ben-
eﬁts although some longitudinal variation in PASAT scores was
observed, potentially due to practice effects and changes in the
study population over time. The improved cognitive perform-
ance in patients who underwent early treatment was consistent
with earlier analyses from BENEFIT.4 12 PASAT results suggest
that minimising inﬂammation through treatment with IFNB1b
in the early stages of the disease may preserve cognitive capacity
of patients with MS.
By contrast with these endpoints where the treatment arms
displayed differences, EDSS, MSFC total z-score, time to ﬁrst
escalation therapy, FAMS-TOI and EQ-5D scores did not differ
between the groups, but generally showed little change over the
course of the study. In general, disease activity remained low for
most patients over the 8-year period of the study in both
groups. Median EDSS scores at year 8 were 1.5 and only 13.7%
of patients participating in the Extension study reached sus-
tained EDSS 3 at any time during the 8-year period. For com-
parison, in a natural history cohort of patients with
relapsing-remitting MS published by Scalfari et al13, and in a
more contemporary partially treated cohort reported by Leray
et al14 (with a mean time between clinical onset and treatment
start of 7.4 years), the median time to sustained EDSS 3 was
Table 2 EDSS and treatment exposure
Early treatment Delayed treatment
Total BENEFIT extension
population
Mean (SD) Median (IQR) Mean (SD) Median (IQR) Mean (SD) Median (IQR)
EDSS score at year 8* 1.87 (1.29) 1.5 (1.0 to 2.5) 1.56 (1.22) 1.5 (1.0 to 2.0) 1.75 (1.27) 1.5 (1.0 to 2.5)
Change in EDSS from baseline to year 8*,† 0.38 (1.22) 0.5 (−0.5 to 1.0) 0.07 (1.11) 0.0 (−0.5 to 0.50) 0.25 (1.18) 0.0 (−0.5 to 1.0)
Change in EDSS from baseline to LESO (%)‡
Improved (≤−1.0) 22.5 18.9 21.1
Stable (>−1.0 to <1.0) 43.8 52.8 47.2
Worsened (≥1.0) 33.7 28.3 31.7
Sustained EDSS progression in the BENEFIT Extension study, n (%)‡,§
≥1 step 40 (22.5) 26 (24.5) 66 (23.2)
≥2.5 steps 7 (3.9) 2 (1.9) 9 (3.2)
Sustained EDSS thresholds in the BENEFIT Extension study, n (%)‡,§
≥3 21 (11.8) 18 (17.0) 39 (13.7)
≥4 9 (5.1) 4 (3.8) 13 (4.6)
≥6 3 (1.7) 0 (0) 3 (1.1)
Interferon beta-1b exposure from the beginning of BENEFIT until the end of the extension study
Median, months¶ 84.0 53.4 70.6
*n=181 (early treatment: n=109, delayed treatment: n=72). Includes patients who had a visit at year 8.
†Baseline EDSS is defined as lowest of the EDSS scores obtained during BENEFIT screening or baseline.
‡n=284 (early treatment: n=178, delayed treatment: n=106). Includes patients who participated in the extension study.
§Unadjusted for duration of observation. Sustained EDSS progression assumed an increase of ≥1 point compared with the lowest EDSS score during screening or baseline which was
confirmed at the first scheduled visit after at least 140 days (including values obtained during relapses) and persisted for a minimum of one and all further following EDSS values
measured at all subsequent scheduled or unscheduled visits after the confirming visit. Includes patients with onset of sustained EDSS progression at any time during the 8-year period.
¶n=278 (early treatment: n=178, delayed treatment: n=100). Includes patients who participated in the extension study and took at least one dose of IFNB-1b during the 8-year period.
EDSS, Expanded Disability Status Scale; LESO, last extension study observation.
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10 years from disease onset.14 The number of patients in
BENEFIT reaching EDSS 3 thus seems smaller than could be
expected, suggesting an impact of early treatment on disability
progression. The observed long-term disease stability was also
reﬂected in the low number of patients requiring escalation
therapy in both arms. NAb status measured at the last visit of
the interventional trial period did not result in any discernible
differences in clinical outcomes. Patients who were NAb− at
that time would be unlikely to have converted to NAb+ in the
extension study.
Although the terms early and delayed treatment have been
applied to the different treatment groups in this analysis of the
BENEFIT study, it should be noted that both groups of patients
started treatment within the ﬁrst 2 years from CIS (eg, relatively
early in the course of their disease). Consequently, there were
only minor differences in treatment exposure between these
groups. Despite the relatively small difference in time on treat-
ment, beneﬁts of early treatment on ARR and disease conver-
sion were observed with up to 8.7 years of follow-up.
Long-term retention in BENEFITwas relatively high, support-
ing the generally favourable tolerability of treatment with
IFNB1b. No new safety signals were detected. FAMS-TOI and
EQ-5D scores were relatively high and stable during the 8 years
of follow-up, suggesting that medication allowed the majority of
patients to maintain QoL.
The ﬁndings from this study are largely in agreement with
those of the Controlled High Risk Avonex MS Prevention Study
in Ongoing Neurological Surveillance (CHAMPIONS) study of
the efﬁcacy of intramuscular interferon beta-1a for patients with
a CIS.15 16 With long-term follow-up (8 years in BENEFIT,
10 years in CHAMPIONS) both trials reported comparable
effects of early treatment on rates of CDMS progression and
ARR, with most patients also showing little or no EDSS progres-
sion. However, there were some methodological differences
between CHAMPIONS and BENEFIT, including differences in
the length of blinding and preplanned follow-up (3 vs 5 years in
both cases).15 Additionally, the BENEFIT population was slightly
different from the CHAMPIONS population, all of whom were
treated with corticosteroids at CIS (vs 70.9% in BENEFIT), and
who tended to be older (median of 34 vs 30 years at baseline in
BENEFIT).16 17 Overall, extension study enrolment was lower in
CHAMPIONS (40.5% compared with 60.7% in BENEFIT).16
Last, CHAMPIONS did not report cognitive outcomes.16
Key factors of the present study that are critical to assessing its
validity include the potential for ascertainment bias in the study
population, differences in medication exposure across treatment
arms, and the potential for gaps in patient observation.
Compared with other studies of CIS,16 18 ascertainment in the
BENEFIT Extension study was relatively high. Additionally, dif-
ferences in baseline characteristics were minimal, suggesting
limited selection bias. By contrast, on-study outcomes after
5 years showed that patients with more active disease entered the
extension, which may have led to an overestimation of disease
progression in the delayed treatment and early treatment groups.
Finally, varying treatments, drug holidays and lack of adherence
during the observational phase should have lessened any treat-
ment effects and biased the results toward the null hypothesis of
no difference between treatment groups. Despite this possibility,
a consistent beneﬁt of early treatment was identiﬁed.
This extension study showed a low overall disease activity and
progression rate in patients with CIS. Regarding conversion to
CDMS and relapse frequency, early treatment retained signiﬁ-
cant beneﬁts as compared with delayed treatment. These ﬁnd-
ings and the benign long-term safety proﬁle of IFNB1b, support
the early initiation of such treatment in patients with CIS. The
observed low EDSS progression and relapse rates in BENEFIT
—both regarded as positive long-term predictors13—give hope
that early treatment might have a positive inﬂuence on long-
term outcomes beyond the ﬁrst 8 years of treatment. In order to
better understand the chronic course of this disease, we remain
committed to continued follow-up of this patient cohort,
including further assessment of imaging outcomes.
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